血清可溶性核因子-κB 配体受体在糖皮质激素治疗后发生变化，反映了成骨细胞对其表达的调节。

Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.

机构信息

Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan.

出版信息

J Clin Endocrinol Metab. 2012 Oct;97(10):E1909-17. doi: 10.1210/jc.2012-1971. Epub 2012 Jul 12.

DOI:10.1210/jc.2012-1971

PMID:22791764

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3462941/

Abstract

CONTEXT

Osteoporosis is a serious complication of systemic glucocorticoid therapy. The role of serum soluble receptor activator for nuclear factor-κB ligand (RANKL) in glucocorticoid-induced osteoporosis remains unclear.

OBJECTIVE

The objective of the study was to clarify the influence of serum soluble RANKL on the osteoprotegerin (OPG)/RANKL/receptor activator for nuclear factor-κB system in patients with systemic autoimmune diseases receiving glucocorticoid therapy.

PATIENTS AND METHODS

Sixty patients (40 women) with systemic autoimmune diseases who received initial glucocorticoid therapy with prednisolone (30-60 mg/d) plus bisphosphonate therapy were prospectively enrolled. Serum soluble RANKL and OPG levels were measured at 0, 1, 2, 3, and 4 wk after starting glucocorticoid therapy. The effects of dexamethasone on production of RANKL and OPG mRNA and protein by cultured normal human osteoblasts were evaluated by RT-PCR and ELISA, respectively.

RESULTS

The mean serum soluble RANKL level of the patients was unchanged by glucocorticoid therapy. Because the distribution of serum soluble RANKL was bimodal, the patients were stratified into two groups. Serum soluble RANKL decreased significantly in the higher soluble RANKL group (≥0.16 pmol/liter), whereas it increased significantly in the lower soluble RANKL group. The mean serum OPG level of the patients decreased significantly. Bone mineral density increased in the higher soluble RANKL group after starting glucocorticoid therapy, whereas it decreased in the lower soluble RANKL group. In cultures of unstimulated human osteoblasts, RANKL mRNA expression was increased and OPG mRNA was decreased by dexamethasone. Up-regulation of RANKL and OPG mRNA by IL-6 was suppressed by dexamethasone.

CONCLUSION

Serum soluble RANKL might be a useful marker of bone remodeling in patients with systemic autoimmune diseases receiving glucocorticoid therapy.

摘要

背景

骨质疏松症是全身性糖皮质激素治疗的严重并发症。血清可溶性核因子-κB 配体受体激活剂（RANKL）在糖皮质激素诱导的骨质疏松症中的作用尚不清楚。

目的

本研究旨在阐明血清可溶性 RANKL 对接受糖皮质激素治疗的系统性自身免疫性疾病患者的护骨素（OPG）/RANKL/受体激活剂核因子-κB 系统的影响。

患者和方法

前瞻性纳入 60 例（40 名女性）接受初始糖皮质激素治疗（泼尼松龙 30-60mg/d）加双膦酸盐治疗的系统性自身免疫性疾病患者。在开始糖皮质激素治疗后 0、1、2、3 和 4 周时测量血清可溶性 RANKL 和 OPG 水平。通过 RT-PCR 和 ELISA 分别评估地塞米松对培养的正常人成骨细胞中 RANKL 和 OPG mRNA 和蛋白产生的影响。

结果

患者的血清可溶性 RANKL 水平在糖皮质激素治疗中无变化。由于血清可溶性 RANKL 的分布呈双峰型，将患者分为两组。较高可溶性 RANKL 组（≥0.16pmol/L）的血清可溶性 RANKL 显著下降，而较低可溶性 RANKL 组的血清可溶性 RANKL 显著升高。患者的血清 OPG 水平显著降低。开始糖皮质激素治疗后，较高可溶性 RANKL 组的骨密度增加，而较低可溶性 RANKL 组的骨密度降低。在未受刺激的人成骨细胞培养物中，地塞米松增加了 RANKL mRNA 的表达并降低了 OPG mRNA 的表达。地塞米松抑制了 IL-6 对 RANKL 和 OPG mRNA 的上调。

结论

血清可溶性 RANKL 可能是接受糖皮质激素治疗的系统性自身免疫性疾病患者骨重建的有用标志物。

相似文献

Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.

J Clin Endocrinol Metab. 2012 Oct;97(10):E1909-17. doi: 10.1210/jc.2012-1971. Epub 2012 Jul 12.

[Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008 Oct;22(10):1161-4.

[Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Jul;23(7):777-80.

Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand.

Bone. 2012 Sep;51(3):515-23. doi: 10.1016/j.bone.2012.05.011. Epub 2012 May 23.

Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.

Am J Physiol Endocrinol Metab. 2016 Sep 1;311(3):E587-93. doi: 10.1152/ajpendo.00219.2016. Epub 2016 Jul 26.

Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.

Bone. 2006 May;38(5):652-61. doi: 10.1016/j.bone.2005.10.004. Epub 2005 Nov 17.

Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.

Eur J Pharmacol. 2011 Jan 15;650(2-3):682-7. doi: 10.1016/j.ejphar.2010.10.058. Epub 2010 Nov 2.

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.

Endocrinology. 1999 Oct;140(10):4382-9. doi: 10.1210/endo.140.10.7034.

Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.

J Immunol. 2007 Jan 1;178(1):192-200. doi: 10.4049/jimmunol.178.1.192.

[Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats].

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Oct;31(10):1714-7.

引用本文的文献

Effectiveness of Daily Teriparatide in Managing Glucocorticoid-Induced Osteoporosis in Rheumatic Disease Patients After Switching From Bisphosphonate Therapy.

Cureus. 2025 Apr 17;17(4):e82471. doi: 10.7759/cureus.82471. eCollection 2025 Apr.

High-Dose Intravenous Steroid Treatment Seems to Have No Long-Term Negative Effect on Bone Mineral Density of Young and Newly Diagnosed Multiple Sclerosis Patients: A Pilot Study.

Biomedicines. 2023 Feb 17;11(2):603. doi: 10.3390/biomedicines11020603.

Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients.

Diagnostics (Basel). 2021 Dec 28;12(1):62. doi: 10.3390/diagnostics12010062.

The Utility of Biomarkers in Osteoporosis Management.

Mol Diagn Ther. 2017 Aug;21(4):401-418. doi: 10.1007/s40291-017-0272-1.

Blockade of interleukin-6 receptor enhances the anti-arthritic effect of glucocorticoids without decreasing bone mineral density in mice with collagen-induced arthritis.

Clin Exp Immunol. 2015 Nov;182(2):154-61. doi: 10.1111/cei.12685. Epub 2015 Aug 31.

Effect of r-Mt-Cpn10 on human osteoblast cells.

Int J Clin Exp Med. 2014 Sep 15;7(9):2779-86. eCollection 2014.

本文引用的文献

Update on glucocorticoid-induced osteoporosis.

Rheum Dis Clin North Am. 2011 Aug;37(3):415-31, vi. doi: 10.1016/j.rdc.2011.07.003.

Glucocorticoid-induced osteoporosis.

Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S93-8. Epub 2011 Oct 21.

Relationship between serum RANKL and RANKL in bone.

Osteoporos Int. 2011 Oct;22(10):2597-602. doi: 10.1007/s00198-011-1740-9. Epub 2011 Aug 18.

Vitamin D and autoimmune rheumatic diseases.

Rheumatology (Oxford). 2009 Mar;48(3):210-2. doi: 10.1093/rheumatology/ken394. Epub 2008 Oct 17.

CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.

J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. doi: 10.1210/jc.2007-0646. Epub 2007 Sep 25.

Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels.

J Cell Biochem. 2008 Jan 1;103(1):335-45. doi: 10.1002/jcb.21414.

Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.

Bone. 2006 May;38(5):652-61. doi: 10.1016/j.bone.2005.10.004. Epub 2005 Nov 17.

Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.

J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31. doi: 10.1210/jc.2005-0794. Epub 2005 Aug 16.

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

J Bone Miner Metab. 2005;23(2):105-9. doi: 10.1007/s00774-004-0596-x.

The OPG/RANKL/RANK system in metabolic bone diseases.

J Musculoskelet Neuronal Interact. 2004 Sep;4(3):268-75.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

血清可溶性核因子-κB 配体受体在糖皮质激素治疗后发生变化，反映了成骨细胞对其表达的调节。

Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.

机构信息

Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan.

出版信息

J Clin Endocrinol Metab. 2012 Oct;97(10):E1909-17. doi: 10.1210/jc.2012-1971. Epub 2012 Jul 12.

DOI:10.1210/jc.2012-1971

PMID:22791764

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3462941/

Abstract

CONTEXT

OBJECTIVE

PATIENTS AND METHODS

RESULTS

CONCLUSION

Serum soluble RANKL might be a useful marker of bone remodeling in patients with systemic autoimmune diseases receiving glucocorticoid therapy.

摘要

背景

骨质疏松症是全身性糖皮质激素治疗的严重并发症。血清可溶性核因子-κB 配体受体激活剂（RANKL）在糖皮质激素诱导的骨质疏松症中的作用尚不清楚。

目的

本研究旨在阐明血清可溶性 RANKL 对接受糖皮质激素治疗的系统性自身免疫性疾病患者的护骨素（OPG）/RANKL/受体激活剂核因子-κB 系统的影响。

患者和方法

结果

结论

血清可溶性 RANKL 可能是接受糖皮质激素治疗的系统性自身免疫性疾病患者骨重建的有用标志物。

血清可溶性核因子-κB 配体受体在糖皮质激素治疗后发生变化，反映了成骨细胞对其表达的调节。

Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.

机构信息

出版信息

CONTEXT

OBJECTIVE

PATIENTS AND METHODS

RESULTS

CONCLUSION

背景

目的

患者和方法

结果

结论

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

血清可溶性核因子-κB 配体受体在糖皮质激素治疗后发生变化，反映了成骨细胞对其表达的调节。

Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.

机构信息

出版信息

CONTEXT

OBJECTIVE

PATIENTS AND METHODS

RESULTS

CONCLUSION

背景

目的

患者和方法

结果

结论